Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

Abstract

CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less-than-perfect correspondence is expected. Automated assays are likely to increase the utility of CSF biomarkers.